The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
|Videos|June 17, 2020
COVID-19: Treating Lupus Amid Hydroxychloroquine Stockpiling
Author(s)Contagion® Editorial Staff
Vibeke Strand, MD, MACR, FACP, discusses patients who are having a hard time getting their usual supplies of HCQ.
Advertisement
Segment Description: Vibeke Strand, MD, MACR, FACP, Adjunct Clinical Professor in the Division of Immunology/Rheumatology professor at Stanford University School of Medicine, discusses patients who are having a hard time getting their usual supplies of HCQ.
Related Coverage: FDA Revokes Emergency Authorization for Chloroquine, Hydroxychloroquine
The US Food and Drug Administration (FDA) has revoked the Emergency Use Authorization (EUAs) for hydroxychloroquine and chloroquine in treating coronavirus 2019 (COVID-19).
The decision comes with context in a letter written by Denis M. Hinton, chief scientist of the FDA, to the Biomedical Advanced Research and Development Authority (BARDA) on Monday morning. BARDA Deputy Assistant Secretary and Director of the Medical Countermeasure Programs Gary L. Disbrow, PhD, originally wrote the FDA requesting the 2 malaria drugs be revoked of their EUAs on the basis of continuously evolving public health response information.
Read the
Advertisement
Related to this article
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.